Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Sodium-glucose co-transporter 2 inhibitors and bladder cancer - a causal association or detection bias? An international multicenter cohort study.

EF 2018-19

Résumé
Type 2 diabetes is one of the fastest growing diseases in Canada, with approximately 60,000 new patients diagnosed each year. In recent years, there have been major advancements in the treatment of type 2 diabetes with the discovery of new drug classes, such as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors have become increasingly popular, as they effectively lower blood sugar levels without the side effects of other antidiabetic drugs. However, these drugs have been associated with frequent urinary tract infections, and there are signals from trials that they may be associated with an increased risk of bladder cancer. To date, however, no study has been conducted in the real-world setting to assess this association. Thus, to address this gap in knowledge, I will conduct a multicenter cohort study among patients with type 2 diabetes using data sources from Canada, Europe and the Middle East. As a possible association may be explained by increased screening of the urinary tract, this international study will be specifically designed to differentiate between a possible biological effect and detection bias. Thus, this study will provide much needed information on the safety of SGLT2 inhibitors, and will be of value to regulatory agencies, physicians, and patients.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
396360
Name
Abrahami Devin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Sodium-glucose co-transporter 2 inhibitors and bladder cancer - a causal association or detection bias? An international multicenter cohort study.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Bladder Cancer; Health Outcomes; International Multicenter Cohort Study; Pharmacoepidemiology; Propensity Score; Type 2 Diabetes
Abstract
Type 2 diabetes is one of the fastest growing diseases in Canada, with approximately 60,000 new patients diagnosed each year. In recent years, there have been major advancements in the treatment of type 2 diabetes with the discovery of new drug classes, such as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors have become increasingly popular, as they effectively lower blood sugar levels without the side effects of other antidiabetic drugs. However, these drugs have been associated with frequent urinary tract infections, and there are signals from trials that they may be associated with an increased risk of bladder cancer. To date, however, no study has been conducted in the real-world setting to assess this association. Thus, to address this gap in knowledge, I will conduct a multicenter cohort study among patients with type 2 diabetes using data sources from Canada, Europe and the Middle East. As a possible association may be explained by increased screening of the urinary tract, this international study will be specifically designed to differentiate between a possible biological effect and detection bias. Thus, this study will provide much needed information on the safety of SGLT2 inhibitors, and will be of value to regulatory agencies, physicians, and patients.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Abrahami, Devin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~